CMPX CEO Schuetz reports RSU tax withholding, 6.44M shares held

Rhea-AI Filing Summary

Compass Therapeutics, Inc. (CMPX) reported an insider ownership update for Chief Executive Officer and Director Thomas J. Schuetz. On 11/16/2025, 44,025 shares of common stock were withheld at a price of $4.83 per share to cover tax obligations arising from the vesting of restricted stock units (RSUs). After this tax withholding transaction, Schuetz beneficially owns 6,436,800 shares of Compass Therapeutics common stock.

The filing notes that 250,000 of these shares relate to unvested RSUs granted on February 8, 2023, which vest in four equal annual installments starting on February 8, 2024. An additional 478,125 shares relate to unvested RSUs granted on January 9, 2024, also vesting in four equal annual installments beginning on January 9, 2025. Each RSU represents a contingent right to receive one share of common stock, subject to continued service-based vesting conditions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schuetz Thomas J.

(Last) (First) (Middle)

C/O COMPASS THERAPEUTICS, INC.

80 GUEST ST., SUITE 601

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Compass Therapeutics, Inc. [ CMPX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
11/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/16/2025		F(1)		44,025	D	$4.83	6,436,800(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

2. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025.

	/s/ Thomas J. Schuetz	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CMPX report for Thomas J. Schuetz?

The company reported that Thomas J. Schuetz, Chief Executive Officer and Director of Compass Therapeutics, Inc. (CMPX), had 44,025 shares of common stock withheld on 11/16/2025 to cover tax obligations related to the vesting of restricted stock units.

How many CMPX shares does Thomas J. Schuetz own after the reported transaction?

Following the reported tax withholding transaction, Thomas J. Schuetz beneficially owns 6,436,800 shares of Compass Therapeutics common stock in direct ownership.

What was the price used for the CMPX shares withheld for taxes?

The shares withheld to cover tax obligations were valued at a price of $4.83 per share in connection with the vesting of restricted stock units.

What are the terms of the February 8, 2023 RSU grant reported for CMPX?

The filing states that 250,000 shares relate to unvested RSUs granted on February 8, 2023. Each RSU represents a contingent right to receive one share of CMPX common stock and is subject to service-based vesting, in four equal annual installments starting on February 8, 2024.

What are the terms of the January 9, 2024 RSU grant reported for CMPX?

The filing notes that 478,125 shares relate to unvested RSUs granted on January 9, 2024. These RSUs vest in four equal annual installments, with the first installment vesting on January 9, 2025, and each RSU is a contingent right to receive one share of common stock.

What roles does Thomas J. Schuetz hold at Compass Therapeutics, Inc.?

Thomas J. Schuetz is identified in the filing as both a Director and an Officer of Compass Therapeutics, Inc., serving in the role of Chief Executive Officer.